The week started with a deal in the pharma sector regarding the manufacturing of Moderna’s COVID-19 vaccine
Moderna and Novavax agreed with the South Korean government
to manufacture the vaccine, as the country has lately been under pressure to
secure more and faster deliveries. South Korea confirmed access to 40 million
doses, according to authorities.
The agreement came after the US and the South Korean
presidents – Joe Biden and Moon Hae-in – agreed on a partnership through which
the first will provide vaccinations for 550,000 South Korean soldiers. The
partnership will combine the US expertise and Korean manufacturing capacity.
Moderna and Novavax are not the first pharma companies to
close this deal with the South Korean government. Among the COVID-19 vaccine
produced there are AstraZeneca’s and Russia’s Sputnik V.
So far, the country has vaccinated less than 10% of its 52
million people. By September, it aims to inoculate at least 70%. Overall, it
ordered approx. 192 million vaccine doses from AstraZeneca, Pfizer, Novavax,
Moderna, Johnson & Johnson.
Following the news, Moderna stock price went up 1.6%.
Sources: cnbc.com, reuters.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Palo Alto Networks beat Q3 2021 expectations
Next Article
AutoZone posts stronger-than-expected profit & sales
